(Source: HBM Healthcare Investments AG) Microsoft Word - Press Release_ASN2015_04Nov2015_FINAL.docx Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week NEWTON, Mass. - Nov. 12, 2015 - Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non- systemic oral protein therapeutics to treat metabolic and orphan diseases, presented successful results from the first Phase 2 trial of ALLN-177 (NCT02289755) at the American Society of Nephrology (ASN) Kidney Week 2015 on Saturday, November 7th. ALLN-177 is currently being developed for the...
↧